Gregory J. Divis - 20 Feb 2024 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Chief Executive Officer, Director
Signature
/s/ Jerad G. Seurer, as Attorney-in-Fact
Issuer symbol
AVDL
Transactions as of
20 Feb 2024
Net transactions value
$0
Form type
4
Filing time
04 Mar 2024, 06:24:03 UTC
Previous filing
10 Aug 2023
Next filing
10 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Award $0 +600,000 $0.000000 600,000 20 Feb 2024 ADSs 600,000 $13.57 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options become exercisable as to 150,000 ADSs on each of the first four anniversaries after the 2/20/2024 grant date.
F2 The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.